Creation and application of psychoactive designer drugs data library using liquid chromatography with photodiode array spectrophotometry detector and gas chromatography-mass spectrometry.
In order to quickly confirm a potentially hazardous psychoactive designer drug (a compound in which part of the molecular structure of a stimulant or narcotic has been modified), we created a psychoactive drugs data library by performing analysis using liquid chromatography with photodiode array spectrophotometry (LC/PDA) and gas chromatography-mass spectrometry (GC/MS). The data in this library consist of the LC capacity factor (k') ratios in relation to the internal standard, the ultraviolet (UV) spectra and the MS spectra of 104 compounds. By performing a comparative study of the data in this report with the analytical data for commercial and illegal drug products, it is possible to quickly identify the psychoactive designer drugs in 205 purchased products by using the library. Further, it is possible to analogize the structure of drugs for which there is no matching data in the library using similar data. Furthermore, when structural isomers of controlled substances have detected from the presented library, similarity of their biological effects on human will be predicted, thus leading to regulate their public circulation. Examples of these types of isomers include, for instance, the narcotic 3,4,5-trimethoxyamphetamine (TMA) and its positional isomers 2,4,5-trimethoxyamphetamine (TMA-2) and 2,4,6-trimethoxyamphetamine (TMA-6), or the narcotic 1-(3-chlorophenyl)piperazine (3CPP) and its isomers 1-(o-chlorophenyl)piperazine (2CPP) and 1-(p-chlorophenyl)piperazine (4CPP). Differentiation of these compounds is necessary in regulating them, and we report here the results of a study of a method to confirm these compounds using the present library.
Takahashi
Misako
M
Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunin-cho, Shinjyuku-ku, Tokyo 169-0073, Japan. Misako Takahashi@member.metro.tokyo.jp
Nagashima
Machiko
M
Suzuki
Jin
J
Seto
Takako
T
Yasuda
Ichirou
I
Yoshida
Takemi
T
D000662:Amphetamines / Q000032:analysis; D002853:Chromatography, Liquid / Q000379:methods*; D015198:Designer Drugs / Q000032:analysis*; D008401:Gas Chromatography-Mass Spectrometry / Q000379:methods*; D008956:Models, Chemical; D009294:Narcotics / Q000032:analysis; D004364:Pharmaceutical Preparations / Q000032:analysis; D010879:Piperazines / Q000032:analysis; D011619:Psychotropic Drugs / Q000032:analysis*; D013053:Spectrophotometry / Q000379:methods*; D014466:Ultraviolet Rays
D000662:Amphetamines; D015198:Designer Drugs; D009294:Narcotics; D004364:Pharmaceutical Preparations; D010879:Piperazines; D011619:Psychotropic Drugs; C521830:2,4,5-trimethoxyamphetamine; C015068:1-(3-chlorophenyl)piperazine